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Recent studies have established that the orexin system is a critical regulator of 
sleep/wake states. Deficiency of orexin signaling results in the sleep disorder 
narcolepsy-cataplexy in humans, dogs, and rodents. These findings have brought 
about the possibility of novel therapies for sleep disorders including narcolepsy-
cataplexy. Furthermore, accumulating evidence has indicated that the orexin system 
regulates sleep and wakefulness through interactions with neuronal systems that 
regulate emotion, reward, and energy homeostasis. This review presents and discusses 
the current understanding of the integrative physiology of the orexin system. 
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Since its discovery in 1998, the field of orexin biology has grown rapidly. In 
the last decade, more than 1700 articles on orexin research have been published. 
Information on the role of the orexin system in the pathophysiology of narcolepsy-
cataplexy has had a huge impact on studies of sleep and wakefulness and on other 
areas of inquiry. Scientists have used a multidisciplinary approach to understand 
various aspects of the physiological functions of orexin peptides, and their efforts 
have uncovered crucial roles of the orexin system in the integrative physiology of 
sleep/wake, energy homeostasis, and the reward systems. Orexin biology has also 
been applied to the diagnosis and treatment of sleep-related disorders. Living in the 
post-genome era, the great success story of orexin biology has driven many 
researchers to dig up novel bioactive peptides and their receptors for further discovery 
of novel physiology and clinical treatments. 
 
Discovery of orexin peptides 
 Orexin peptides (orexin-A and orexin-B) were initially identified by our group 
as endogenous ligands for two orphan G-protein coupled receptors (GPCR) [1]: 
GPCRs, for which endogenous ligands are unknown, are referred to as “orphan” 
GPCRs. Since intracerebroventricular (ICV) injection of these peptides in rats acutely 
stimulated food consumption (discussed below), they were named orexin-A and -B 
after the Greek word ‘orexis’, meaning appetite. Orexin-A and -B are produced by 
cleavage of a single precursor polypeptide, prepro-orexin. Mammalian orexin-A is a 
33 amino acid peptide that has two sets of intrachain disulfide bonds and undergoes 
pyroglutamylation and amidation at its N- and C-terminals, respectively, while orexin-
B is a 28 amino acid linear peptide with C-terminal amidation. Around the same time, 
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de Lecea et al. searched mRNA expressed specifically within the hypothalamus and 
identified a cDNA encoding a polypeptide identical to prepro-orexin, and named the 
putative mature peptides hypocretin-1 (orexin-A) and -2 (orexin-B) [2]. Although the 
initial estimated structures of hypocretin-1 and hypocretin-2 were not the same as 
those of orexin A and orexin B, the terms ‘orexin’ and ‘hypocretin’ are used as 
synonyms in many papers. 
 The actions of orexins are mediated by two receptors, named orexin 1 (OX1R) 
and orexin 2 (OX2R) receptors (also named HCRTR1 and HCRTR2) [1]. OX1R has 
one-order higher affinity for orexin-A than for orexin-B, while OX2R binds orexin-A 
and orexin-B with similar affinities. OX1R primarily couples to the Gq/11 subclass of 
heterotrimeric G proteins, while OX2R coupled to Gq/11 or Gi/o in a neuronal cell line 
[3]. 
 Neurons expressing orexins (orexin neurons) are distributed within an area 
consisting of three contiguous hypothalamic regions: lateral hypothalamus (LH), 
perifornical area (PFA) and dorsomedial hypothalamic nucleus (DMH) [1, 2, 4-6]. 
The number of these neurons has been estimated to total around 3000 in the rat and 
50,000 in the human brain. In contrast to the restricted localization of their cell bodies, 
orexin neurons send projections widely throughout the central nervous system (CNS), 
including the cerebral cortex, limbic system (such as the amygdala, bed nucleus of 
stria terminalis (BST) and hippocampus), hypothalamus (such as the arcuate nucleus 
(ARC) and tuberomammillary nucleus (TMN)), and brain stem area (such as the 
central gray, locus coeruleus (LC), and raphe nuclei) [4-7]. Consistent with the broad 
projections of orexin neurons, OX1R and OX2R show partly overlapping but distinct 
distributions of their mRNA throughout the CNS [8-10]. For instance, nuclei such as 
the LC, laterodorsal tegmental nucleus (LDT), and pedunculopontine tegmental 
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nucleus (PPT) mainly express OX1R mRNA, while those including the TMN, nucleus 
accumbens (NAc), and septal nuclei mainly express OX2R mRNA. These 
distributions suggest partly overlapping and partly distinct roles of these two receptors. 
 
Disruption of orexin system causes narcolepsy-cataplexy 
 Soon after the discovery of orexin peptides, two independent studies utilizing 
dog forward genetics and mouse reverse genetics elucidated a causal linkage between 
disruption of the orexin system and narcolepsy-cataplexy. Subsequent studies showed 
that loss of orexin neurons is observed in human narcolepsy-cataplexy patients. These 
studies have revealed that orexin is essential for stability of sleep/wake states in 
various species, namely dog, mouse and human. 
 
Human narcolepsy-cataplexy 
Human narcolepsy is a debilitating neurological disease that affects 
approximately 1 in 2000 individuals in the United States [11]. Onset of the condition 
is usually during adolescence (around 12-14 years old). A cardinal symptom of the 
disorder is excessive daytime sleepiness (an insurmountable urge to sleep), which 
manifests itself primarily when the subject falls asleep at inappropriate times (“sleep 
attacks”). When normal individuals fall asleep, a certain period of non-REM (NREM) 
sleep (approximately 90 minutes) usually precedes rapid eye movement (REM) sleep. 
However, the latency of REM sleep is markedly reduced in narcolepsy patients. REM 
sleep is sometimes observed immediately after wakefulness (sleep-onset REM). The 
existence of “sleep-onset REM periods” is one of the diagnostic criteria of narcolepsy. 
In patients, nocturnal sleep is also fragmented and is often accompanied by 
hypnagogic hallucinations, vivid dreaming, and sleep paralysis, which usually occur 
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near sleep onset. Narcolepsy patients often suffer from a condition called “cataplexy”, 
which is characterized by a sudden weakening of muscle tone (muscle atonia), 
ranging from jaw dropping and speech slurring to complete bilateral collapse of the 
postural muscles. These attacks are often triggered by emotional stimuli, such as 
laughter, excitement, and pleasure. Consciousness is preserved during cataplexy. 
Around 10% of narcolepsy patients do not suffer from cataplexy, although they 
experience excessive daytime sleepiness. Therefore, narcolepsy with cataplexy is 
sometimes referred to as “narcolepsy-cataplexy” to stress the occurrence of cataplexy. 
Symptoms of narcolepsy-cataplexy can be divided into two pathological 
phenomena. One is the inability to maintain a consolidated awake period, 
characterized by abrupt transitions to NREM sleep (i.e. dysregulation of NREM sleep 
onset). This phenomenon manifests clinically as excessive daytime sleepiness or a 
sleep attack. This symptom is treated with psychostimulants, such as methylphenidate, 
methamphetamine, and modafinil. The other key phenomenon is the pathological 
intrusion of REM sleep into wakefulness (i.e. dysregulation of REM sleep onset): it is 
during these periods that patients may experience cataplexy, hypnagogic 
hallucinations and sleep paralysis. These symptoms are treated with tricyclic 
antidepressants and selective serotonin reuptake inhibitors (SSRI). 
 
Discovery of a causal link between loss of orexin signaling and narcolepsy-
cataplexy 
 Orexin knockout mice exhibit frequent sudden collapses during the dark phase, 
the portion of the circadian rhythm during which there is the most time awake and 
spent in activity.  These attacks resemble human cataplexy attacks [12]. 
Electroencephalogram/electromyogram (EEG/EMG) recordings correlated these 
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attacks with direct transitions from wakefulness to REM sleep, suggesting that they 
are homologous to cataplexy (Fig. 1). Quantitative sleep state parameters in orexin-/- 
mice revealed significantly decreased waking time, increased NREM and REM sleep 
time, decreased REM sleep latency, and, most importantly, a markedly decreased 
duration of waking episodes during the dark phase (i.e. inability to maintain a long 
awake period) (Fig. 1). Around the same time, Mignot and colleagues identified 
mutations in the OX2R gene responsible for inherited canine narcolepsy-cataplexy by 
positional cloning [13]. This canine model of narcolepsy-cataplexy displays 
emotionally triggered cataplexy, fragmented sleep patterns, and excessive daytime 
sleepiness. The phenotype is transmitted as a single autosomal recessive trait (canarc-
1) with full penetrance. These studies in mice and dogs established that genetic 
disruption of orexin signaling causes narcolepsy-cataplexy. 
Subsequently, deficiency of orexin in human narcolepsy-cataplexy, especially 
when accompanied by cataplexy, was confirmed. In contrast to normal control 
individuals, the vast majority of narcoleptic individuals have low or undetectable 
levels of orexin neuropeptides in the cerebrospinal fluid (CSF) [14]. Marked 
reductions of orexin mRNA and immunoreactivity in postmortem brains of 
narcoleptic patients was also shown [15, 16]. No mutation has been found in either the 
prepro-orexin or orexin receptor genes of human narcolepsy-cataplexy patients except 
for an unusually severe, early onset case associated with a mutation in the prepro-
orexin gene that impairs peptide trafficking and processing [15]. A recent finding 
showing concomitant loss of dynorphin, neuronal activity-regulated pentraxin, and 
orexin, which colocalize in orexin neurons, further indicates a loss of orexin neurons, 
rather than selective inhibition of orexin expression, in narcolepsy-cataplexy [17]. 
Based on these observations, as well as the strong association of human narcolepsy-
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cataplexy with certain Human leukocyte antigen (HLA) alleles [18], it has been 
speculated that narcolepsy-cataplexy may result from selective autoimmune 
degeneration of orexin neurons. 
OX2R-/- mice have characteristics of narcolepsy-cataplexy, although their 
behavioral and EEG phenotype is less severe than that found in orexin-/- mice (Fig. 1) 
[19]. They show behavioral arrests that are less frequent and severe than those in 
orexin-/- mice. Electroencephalographically, these mice exhibit fragmentation of 
sleep/wake states but lack frequent direct transitions to REM sleep. OX1R-/- mice do 
not have overt behavioral abnormalities and exhibit only increased fragmentation of 
sleep-wakefulness states (Fig. 1) [20]. Double deletion, OX1R-/-;OX2R-/-, mice appear 
to be a phenocopy of orexin knockout mice (Fig. 1) [20], implying that these two 
receptors are sufficient to mediate regulation of sleep/wake by orexins. Results of 
these mouse reverse genetic studies suggest that normal regulation of wake/NREM 
sleep transitions depends critically on OX2R activation, whereas the profound 
dysregulation of REM sleep control unique to the narcolepsy-cataplexy syndrome 
emerges from loss of signaling through both OX1R- and OX2R-dependent pathways. 
Hara et al. produced transgenic mice in which orexin neurons are ablated by 
expression of a neurotoxic form of ataxin-3, which induces postnatal apoptotic death 
of all orexin neurons by adulthood (orexin neuron-ablated mice) [21]. These adult 
mice show essentially the same phenotype of sleep/wake regulation as orexin-/- mice. 
Therefore, although orexin neurons produce other neurotransmitters such as glutamate 
and dynorphin [22-24], these results demonstrate that orexin is important for 




Clinical potential of orexin peptides 
The finding of a low CSF orexin-A level in patients with narcolepsy-cataplexy 
led to the development of a novel, definitive diagnostic test for this disease [14]. 
Currently, a low orexin-A level in CSF is one of the diagnostic criteria for narcolepsy-
cataplexy according to the 2nd edition of the International Classification of Sleep 
Disorders [25]. 
In addition, the discovery of a causal link between loss of orexin signaling and 
human narcolepsy-cataplexy has brought about the possibility of novel therapies for 
this disease. Currently, excessive sleepiness is treated using psychostimulants, while 
cataplexy is treated with tricyclic antidepressants. γ-hydroxybutyrate (sodium oxybate, 
GHB) is also used to consolidate nocturnal sleep and reduce cataplexy [26]. This 
therapeutic regimen is problematic due to limited effectiveness (psychostimulants, 
tricyclic antidepressants, and GHB), undesirable side effects such as insomnia 
(psychostimulants) or symptom rebound (tricyclic antidepressants and 
psychostimulants), and the potential for abuse (psychostimulants and GHB). Since the 
etiology and disease course in orexin neuron-ablated mice (orexin/ataxin-3 mice) are 
similar to those of human narcolepsy-cataplexy, these mice may represent the most 
accurate pathophysiological model of narcolepsy-cataplexy available [21]. We 
demonstrated rescue of the phenotype of orexin neuron-ablated mice by genetic and 
pharmacological means [27]. Chronic overproduction of orexin peptides from an 
ectopically expressed transgene prevented the development of narcolepsy syndrome in 
orexin neuron-ablated mice. Furthermore, acute ICV administration of orexin-A 
maintained wakefulness, suppressed sleep, and inhibited cataplectic attacks in these 
mice. Intriguingly, ICV administration of orexin-A had stronger arousal effects in 
orexin neuron-ablated mice than in wild-type controls. These results indicate that 
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orexin neuron-ablated mice retain the ability to respond to orexin neuropeptides and 
that spatially targeted secretion of orexin is not necessary to prevent narcoleptic 
symptoms. A similar result was also obtained by Fujiki et al., demonstrating that 
orexin-A intravenously administered at an extremely high dose induced a very short-
lasting anticataplectic effect in an orexin-deficient narcoleptic dog [28]. Unfortunately, 
constitutive production of orexin peptides from a prepro-orexin transgene in mice per 
se caused fragmentation of NREM sleep episodes in the light period, when mice 
spend the most time asleep (T.S., unpublished observation). These results indicate that 
orexin neurons should be turned on and switched off to maintain consolidated 
wakefulness and NREM sleep, respectively. Thus, orexin receptor agonists with half-
lives of several hours (< 12 hours) would be of potential value for treating human 
narcolepsy-cataplexy. Such agonists might also be useful in the treatment of other 
conditions of excessive daytime sleepiness in humans. Conversely, orexin receptor 
antagonists might be useful as safe hypnotics. Indeed, Almorexant, an orally available 
antagonist of OX1R and OX2R, has been reported to increase subjective and objective 
electrophysiological signs of sleep in humans [29], and it is now in Phase III studies. 
 
Regulation of wakefulness by orexin 
 In light of the evidence that deficiency of orexin signaling is associated with 
narcolepsy-cataplexy in animals and humans, there are additional pharmacological, 
anatomical, and electrophysiological data that support the role of the orexin system in 




Neural mechanism of sleep/wake regulation 
Wakefulness is maintained by a complex process involving multiple 
neurotransmitters. Included in this system are histaminergic, noradrenergic and 
serotonergic neurons that diffusely innervate the forebrain, regulating cortical function. 
Other important wake-inducing signals are cholinergic fibers from the basal forebrain 
(BF) and the brain stem (PPT/LDT) that interconnect with key forebrain targets [30, 
31]. Monoaminergic neurons, including LC noradrenergic, raphe serotonergic, and 
TMN histaminergic neurons, project diffusely to the cerebral cortex, thalamus, and 
brainstem, and are thought to promote arousal. They are highly active during 
wakefulness, while their activities are reduced during NREM sleep and their 
discharge almost ceases during REM sleep (REM-off). These monoaminergic neurons 
are believed to suppress activities of PPT/LDT cholinergic neurons. A subset of 
PPT/LDT neurons is active during both wakefulness and REM sleep (W-REM on) 
and project to the thalamus, including the intralaminar nuclei, thalamic relay nuclei, 
and the reticular nucleus of the thalamus. The reticular nucleus is thought to play a 
key role in regulating thalamic activity, and the cholinergic influence is thought to be 
crucial in activating thalamocortical transmission to generate EEG desynchronization 
characteristics of wakefulness and REM sleep. Others are active exclusively during 
REM sleep (REM-on) and are thought to induce REM sleep and REM atonia. 
GABA/galaninergic neurons in the ventrolateral preoptic nucleus (VLPO) of the 
hypothalamus are active during sleep, especially non-REM sleep [31], and are 
considered to comprise a sleep center. VLPO neurons and monoaminergic neurons 
reciprocally inhibit each other. This reciprocal interplay of stimulation and inhibition 




Orexin neurons in regulatory circuit of sleep/wake 
Orexin neurons send projections to nuclei involved in sleep/wake regulation, 
including the LC noradrenergic, raphe serotonergic, TMN histaminergic, PPT/LDT 
and basal forebrain cholinergic neurons (Figs. 2, 3) [12, 32, 33]. Neurons in these 
nuclei express orexin receptors [10]. ICV administration of orexin-A in rodents 
reduces REM and non-REM sleep, and increases wakefulness [34]. More recently, 
Adamantidis et al. demonstrated that direct and selective photostimulation of orexin 
neurons in freely moving mice, in which orexin neurons were genetically targeted to 
express a photo-activatable cation channel (channelrhodopsin-2), increased the 
probability of transitions to wakefulness from either NREM or REM sleep [35]. 
Application of orexin directly into the LC [36], TMN [37], BF cholinergic area 
[38], LDT [39], and lateral preoptic area [40] has effects similar to those of ICV 
injection on sleep/wake states. Especially, several reports demonstrated that 
histaminergic neurons in the TMN play an important role in the arousal-promoting 
effect of orexin. The effect of ICV orexin-A administration is markedly attenuated by 
the histamine H1 receptor antagonist pyrilamine [33], and is absent in H1 histamine 
receptor knockout mice [37]. Taken in conjunction with the facts that OX2R is 
abundantly expressed in the TMN and that OX2R knockout mice exhibit 
fragmentation of sleep/wake states [10, 19], these results suggest that the TMN 
histaminergic system plays a prominent role in mediating the waking effect of orexin-
A. 
In vitro slice electrophysiology studies have shown that orexin increases the 
firing rates of monoaminergic neurons in the LC [32, 41], raphe [42, 43], and TMN 
[33, 44, 45], and in cholinergic neurons in the BF and LDT [46, 47], but has no effect 
on GABAergic neurons in the VLPO [46]. More recent work in cats has shown that 
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orexin-A inhibits cholinergic neurons in the PPT in vivo through activation of 
GABAergic interneurons and GABAergic neurons in the substantia nigra pars 
reticulata [48]. These results indicate that orexin neurons affect the activity of 
PPT/LDT cholinergic neurons both directly and indirectly to regulate arousal and 
REM sleep. 
 At the same time, orexin neurons receive projections from nuclei involved in 
sleep/wake regulation. GABAergic neurons in the preoptic area, including the VLPO, 
densely innervate orexin neurons (Fig. 3) [49, 50]. Orexin neurons are strongly 
inhibited by both the GABAA receptor agonist muscimol and the GABAB receptor 
agonist baclofen [51-53]. Orexin neurons are also innervated by BF cholinergic 
neurons [49]. Carbacol, an agonist at muscarinic receptors, activates a subset of orexin 
neurons [49, 54]. Thus, orexin neurons are inhibited by sleep-promoting neurons and 
activated by wake-promoting BF neurons: this regulation of orexin neurons is 
consistent with their proposed function to stabilize wakefulness. In contrast, wake-
active serotonergic neurons in the medial raphe nuclei send inhibitory projections to 
orexin neurons [49, 51, 55]. Noradrenergic neurons also have inhibitory effects on 
orexin neurons [51, 54, 56]. Serotonergic and noradrenergic inputs hyperpolarize 
orexin neurons through activation of G-protein-regulated inwardly rectifying K+ 
(GIRK or Kir3) channels mediated by 5-HT1A receptors and α2-adrenoceptors, 
respectively [51, 54, 56]. These negative feedback mechanisms may also be important 
for fine adjustment of orexin neuronal activity to stabilize wakefulness. Histamine has 
little effect on orexin neurons [54]. Interestingly, a short 2-hour period of total sleep 
deprivation was reported to change the action of noradrenaline on orexin neurons 
from excitation to inhibition in rats [57]. This mechanism may contribute to the 
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growing sleepiness that accompanies sleep deprivation, although this phenomenon 
was not observed in mice [56]. 
 Feedback circuits mediated by local interneurons may also play important 
roles in the regulation of orexin neurons. In slice preparations, orexin-A and orexin-B 
were reported to depolarize orexin neurons [51]. This effect appears to be mediated by 
orexin-induced excitation of local glutamatergic neurons that regulate orexin neuronal 
activity, in part by presynaptic facilitation of glutamate release. On the other hand, 
GABAergic input from local interneurons to orexin neurons is also important for 
organization of orexin neuronal activity [58]. Orexins activate local GABAergic input 
to orexin neurons. Genetic disruption of this input was reported to produce marked 
sleep/wake abnormality [58]. 
 Horvath and Gao reported unusual synaptic organization of orexin neurons in 
which excitatory synaptic currents and asymmetric synapses exert control on the 
perikarya of these long projective neurons with minimal inhibitory input, which is in 
sharp contrast to the fact that neuronal cell bodies in the central nervous system are 
either dominated by inhibitory inputs (long-projective neurons) or have an 
approximate ratio of excitatory to inhibitory inputs of 1:1 [59]. Arousal is a vital 
behavior in all species. This unique input organization of orexin neurons may be a 
necessary element for the maintenance of a low threshold for arousal and alertness. 
On the other hand, this circuitry may also be an underlying cause of insomnia. 
Consistent with these results, an electrophysiological slice study indicated that orexin 
neurons are tonically activated by glutamatergic neurons [51]. By constrast, the basal 
tone of GABAergic input seems to be low, as GABA antagonists do not influence 
basal activity of orexin neurons. Furthermore, Rao et al. reported that sleep 
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deprivation induced long-term potentiation of synaptic strength at glutamatergic 
synapses on orexin neurons [60]. 
 Based on the known pathophysiology of narcolepsy-cataplexy, orexin neurons 
are expected to be active during wakefulness and to be silent during sleep. Fos 
expression (an indicator of neuronal activity) in orexin neurons in rats is higher during 
the dark phase (active period) than during the light phase (rest period) [61]. Moreover, 
orexin level in CSF peaks during the dark period and decreases during the light period 
[62]. In vivo single unit recordings further confirmed activity patterns of orexin 
neurons across sleep/wake cycles with high temporal resolution. Mileykovskiy et al. 
first developed criteria for identification of orexin neurons based on 
electrophysiological characteristics in anesthetized rats, then recorded the activity of 
orexin neurons in unanesthetized, unrestrained rats [63]. Lee et al., as well as 
Takahashi et al., also recorded from orexin neurons in the LHA and posterior 
hypothalamus of head-fixed rats and mice, respectively, identified through a 
combination of neurobiotin labeling and immunohistochemical staining [64, 65]. 
Essentially, orexin neurons fired most actively during active waking, showed 
decreased discharge during quiet waking, were virtually silent during NREM sleep, 
and were almost silent but exhibited occasional firing during REM sleep. During the 
transition from sleep to wakefulness, orexin neurons fired prior to the onset of EEG 
activation, the EEG sign of wakefulness [64, 65]. In addition, they responded with a 
short latency to an arousing sound stimulus given during sleep, causing EEG 
activation [63, 65]. These characteristics of orexin neurons clearly contrast with those 
of histaminergic neurons, which display waking-specific discharge. Although the 
numbers of cells examined were too small to provide a complete picture of the 
temporal pattern of orexin neuronal activity across sleep/wake cycles, these seminal 
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and laborious studies provide the strongest evidence that these neurons are activated 
during wakefulness and inhibited during sleep. 
 
Orexin neurons as stabilizers of sleep/wake states 
 As discussed above, instability of wake episodes is the characteristic 
abnormality in narcoleptics. Meanwhile, nacroleptics can be roused from sleep and 
their daily amount of wakefulness is relatively similar to that in normal controls. How 
do orexin neurons stabilize wakefulness (Fig. 4)? 
Sleep-active VLPO neurons and wake-active monoaminergic neurons 
reciprocally inhibit each other, constituting a “flip-flop” circuit [31]. In this type of 
circuit, when activity on either side begins to overcome the other, the system will flip 
to one of two possible extremes. Although it is well suited to avoid intermediate states, 
a small perturbation of the activity on one side can easily cause abrupt switching 
between two states, resulting in frequent state transitions. Such a condition resembles 
narcoleptic phenotypes, flip-flopping between wakefulness and sleep. Orexin neurons 
seem to function as a stabilizer of this circuit by enhancing the activity of 
monoaminergic neurons during wakefulness, avoiding state instability caused by 
small perturbations. At the same time, negative feedback input to orexin neurons from 
serotonergic and noradrenergic neurons acts to maintain the activities of orexin and 
monoaminergic neurons within appropriate ranges. During sleep, orexin neurons 
together with monoaminergic neurons are turned off by VLPO GABA/galaninergic 
neurons activated by sleep substances such as adenosine. Adenosine may also inhibit 




Roles of orexin peptides beyond mere global arousal 
 As described earlier, the fact that orexin neurons are much more active during 
active waking than during quiet waking in vivo clearly suggests that the roles of 
orexin extend beyond mere global arousal. Recently, Deadwyler et al. reported that 
systemic and nasal delivery of orexin-A reduced the effects of sleep deprivation on 
cognitive performance in nonhuman primates; interestingly, orexin-A did not produce 
facilitative effects if the animals were not sleep deprived [67]. In slice preparations 
from rat prefrontal cortex, orexin was reported to induce calcium transients in single 
spines postsynaptic to identified thalamocortical boutons [68, 69]. By this cellular 
mechanism, orexinergic projections to the prefrontal cortex may play a role in 
prefrontal or “executive” aspects of alertness and attention. In addition, Deadwyler’s 
finding that the nasal delivery method was significantly more effective than the 
highest dose of intravenous orexin-A tested provides strong evidence for the 
effectiveness of intranasal orexin-A in alleviating the cognitive deficit produced by 
loss of sleep, as well as in the treatment of narcolepsy-cataplexy [67]. 
 
Integrative physiology of the orexin system 
Orexin peptides and feeding behavior: A link between energy homeostasis 
and wakefulness regulation 
Since orexins are expressed in the lateral hypothalamic area, which has long 
been identified as a “feeding center”, and ICV injection of orexin-A increases food 
intake, orexins were initially characterized as orexigenic (appetite-stimulating) factors 
[1, 70-73]. In support of this idea, ICV administration of anti-orexin antibody or an 
OX1R-selective antagonist reduced food intake [74, 75]. In addition, an OX1R-
selective antagonist reduced food intake and ameliorated obesity in leptin-deficient 
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ob/ob mice [76]. Moreover, orexin knockout mice and orexin neuron-ablated mice ate 
less than control wild-type mice [20, 21]. Human narcolepsy patients also have a 
decreased caloric intake, although paradoxically, they show an increased body mass 
index [77, 78]. Similarly, orexin neuron-ablated mice exhibit late-onset obesity [21], 
although the degree of obesity in these mice critically depends on their genetic 
background [79]. This apparent inconsistency will be further discussed later. 
Orexin neurons have dense and reciprocal connections with other 
hypothalamic nuclei regulating feeding behavior, such as the ARC and ventromedial 
hypothalamic nucleus (VMH) [5, 6, 49, 50, 80-82]. Consistent with the dense 
projections of orexin neurons to the ARC, several studies have suggested that the 
increased food intake following orexin-A administration is at least partly mediated by 
activation of neuropeptide Y (NPY) neurons in the ARC [83, 84]. Other events 
involved in orexin-induced feeding behavior include the inhibition of 
proopiomelanocortin neurons in the ARC, which are thought to have an important role 
in leptin-mediated inhibition of food intake [84]. Recent reports also showed that 
infusion of orexin-A into the shell of the nucleus accumbens increased feeding 
behavior [85]. In addition, infusion of the GABAA receptor agonist muscimol into the 
NAc shell strongly induced food intake and simultaneously increased Fos expression 
specifically in orexin neurons [86]. These findings indicate that reciprocal interactions 
between the orexin and reward systems have a role in the regulation of feeding. 
An important difference in effects on feeding between orexins and other 
orexigenic factors, such as NPY and melanin-concentrating hormone (MCH), is that 
orexin increases both food intake and energy expenditure [21, 78, 87], while other 
feeding peptides generally decrease energy expenditure [88]: the latter response is 
more adaptive to conserving energy under food scarcity. Increased energy expenditure 
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by orexin administration seems to be caused by increased wakefulness and locomotor 
activity, as well as an increase in activity of the autonomic nervous system. ICV 
orexin injection increases blood pressure and heart rate. These effects are abolished by 
the administration of blockers of α- or β-adrenoceptors [89]. Moreover, blood 
pressure is 10-15 mmHg lower in orexin knockout mice compared to wild-type mice 
[90, 91]. These results suggest that orexins physiologically stimulate sympathetic 
outflow. In other words, orexin deficiency decreases sympathetic tone, resulting in 
reduced energy expenditure. This may explain why human and mouse narcolepsy-
cataplexy is associated with an increase of body weight despite their hypophagia [21, 
77, 78]. 
Thus, orexin neurons do not simply act as a system that maintains long-term 
body weight homeostasis. Rather, they seem to be necessary for food seeking and 
feeding behavior, especially when animals are faced with food scarcity. Food seeking 
and food intake require more vigilant states and more energy expenditure. Recent 
evidence has suggested that orexin neurons are capable of sensing indicators of 
energy balance and are activated under negative energy balance (Fig. 3). Analysis of 
Fos expression revealed that orexin neurons are activated by hypoglycemia [92]. In 
slice preparations, decreasing the extracellular glucose concentration produced 
depolarization and increased the frequency of action potentials in orexin neurons, 
whereas increasing extracellular glucose concentration induced marked 
hyperpolarization and cessation of action potentials in the same neurons [52, 93]. 
Importantly, this mechanism is sufficiently sensitive to encode variations in glucose 
levels reflecting those occurring physiologically between normal meals [52, 93]. 
Inhibition of orexin neurons by glucose is mediated by tandem-pore K+ (K2P) channels 
[94]. Glucose appears to act at an extracellular site on orexin neurons [94]. The 
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intracellular mechanism that transmits information on extracellular glucose to ion 
channels has not been elucidated, although ATP, Ca2+, and glucose itself have been 
excluded from candidate messengers [94]. Ghrelin, a stomach-derived orexigenic 
peptide, activated 60% of dispersed orexin neurons when applied in a superfused 
solution, with depolarization and an increase in action potential frequency [52]. In 
contrast, bath-application of leptin, an anorexigenic protein hormone secreted by 
adipocytes, was found to robustly inhibit most of the orexin neurons examined, 
causing hyperpolarization and a decrease in firing rate [52]. Notably, insulin exerted 
no direct effect on orexin neurons. 
These abilities of orexin neurons to sense humoral metabolic cues, as well as 
innervations from regions that control metabolism and feeding, including the ARC, 
VMH, and nucleus of the solitary tract (NTS) [49, 50, 80-82], might enable orexin 
neurons to control arousal related to the peripheral energy balance. When faced with a 
negative energy balance due to reduced food availability, mammals respond 
behaviorally with phases of increased wakefulness and alertness, which presumably 
enhances their ability to find food [52, 95, 96]. We previously demonstrated that 
orexin neuron-ablated mice are incapable of this fasting-induced arousal, indicating 
that orexin neurons are necessary for evoking adaptive behavioral arousal during 
fasting [52]. Orexin neurons also regulate the sympathetic nervous system and the 
hypothalamic-pituitary-adrenal (HPA) axis, as discussed earlier and below, 
respectively. Coordinated increases of sympathetic and HPA tone in response to 
fasting-induced arousal directed by orexin neurons may further help animals to 
execute adaptive behavior along with autonomic and neuroendocrine responses. 
Horvath and Gao recently showed that overnight food deprivation increased 
the number of excitatory synapses and synaptic currents onto orexin neurons, which 
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was reversed by re-feeding and blocked by leptin administration [59]. This surprising 
plasticity of orexin neurons further indicates the importance of their role in linking 
energy homeostasis to arousal regulation. Meanwhile, these mechanisms may hinder 
attempts to treat obesity by food restriction. 
 Another way in which orexin neurons contribute to feeding behavior is 
mediating efferent signals from the so-called “food-entrainable circadian oscillator 
(FEO)” to elicit food-anticipatory activity (FAA) and wakefulness, which will be 
discussed in “Orexin peptides and circadian rhythms” [97, 98]. 
 
Orexin peptides and drinking behavior 
 Orexins may act as a mediator that regulates drinking behavior, since ICV 
administration of orexins increases water intake in rats, and orexin-immunoreactive 
varicose axons were observed in the subfornical organ and area postrema - regions 
implicated in drinking behavior [99]. In addition, anti-diuretic hormone arginine-
vasopressin (AVP) directly depolarizes orexin neurons through the V1a receptor [100, 
101]. Similar to food deprivation, wild-type mice display increased locomotor activity 
when dehydrated, presumably increasing the ability of the animals to search for water, 
as well after ICV AVP administration. In contrast, orexin neuron-ablated mice failed 
to exhibit dehydration- and AVP-induced increases in locomotor activity, suggesting a 
key role of orexin neurons in water deprivation-induced hyperlocomotor activity 
[100]. 
 
Orexin peptides and the reward system 
 The roles of orexin neurons in the reward system have been a focus of recent 
attention. Dopaminergic projections of neurons in the midbrain ventral tegmental area 
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(VTA) to the forebrain, particularly to the NAc, have classically been identified as the 
“reward pathway”. Drugs of abuse stimulate this pathway. Orexin neurons have 
reciprocal connections with both the VTA and NAc (Fig. 3) [5, 50, 102]. Orexin 
directly activates VTA dopaminergic neurons through OX1R [103, 104]. On the other 
hand, dopamine can inhibit orexin neurons by acting on α2-adrenoceptors and/or the 
dopamine D2 receptor in slice preparations [54, 56, 105]. 
 Harris et al. recently demonstrated that activation of orexin neurons in the LH 
(but not in the PFA) was strongly linked to preferences for cues associated with drug 
and food rewards in rats [106]. Systemic administration of the selective OX1R 
antagonist SB334867 during training significantly reduced place preference for 
morphine (a µ-opioid receptor agonist). In addition, chemical activation of lateral 
hypothalamic orexin neurons, as well as local administration of orexin-A peptide 
directly into the VTA, reinstated extinguished drug-seeking behavior [106]. Similarly, 
Narita et al. reported that morphine-induced place preference and hyperlocomotion 
observed in wild-type mice were abolished in orexin knockout mice [107]. 
Development of place preference was also blocked by injection of an OX1R 
antagonist into the VTA. Synaptic plasticity induced by orexin in the VTA seems to 
underlie behavioral sensitization to cocaine. Borgland et al. demonstrated that orexin-
A input to VTA dopamine neurons potentiates NMDAR (N-methyl-D-aspartate 
receptor)-mediated neurotransmission through a protein kinase C-dependent insertion 
of NMDARs in synapses on these neurons in slice preparations [108]. Furthermore, in 
vivo administration of an OX1R antagonist blocked locomotor sensitization to cocaine 
and prevented cocaine-induced potentiation of excitatory currents in VTA dopamine 
neurons. These observations indicate a strong functional interaction between the 
orexinergic pathways and the dopaminergic system in the mechanisms of reward and 
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drug addiction. This interaction may underlie the hedonic control of feeding, as well 
as the facilitating role of orexin in male sexual behavior of rats [109]. 
Meanwhile, Boutrel et al. suggested that orexin-A also reinstates cocaine 
seeking by mechanisms different from increased dopamine release [110]. Similarly to 
the results described above, ICV infusion of orexin-A, although ineffective on cocaine 
intake in rats, led to dose-related reinstatement of previously extinguished cocaine-
seeking and food-seeking behavior, and antagonism of OX1R blocked foot shock-
induced reinstatement of extinguished cocaine-seeking. In sharp contrast to the well-
known threshold-lowering effect of cocaine, a drug of abuse that stimulates the VTA-
forebrain dopaminergic pathway, orexin-A significantly elevated the intracranial self-
stimulation (ICSS) threshold in rats, reflecting a decrease in the activity of brain 
reward systems. Orexin-induced reinstatement of cocaine seeking was prevented by 
blockade of the noradrenergic and corticotropin releasing factor (CRF) systems, 
suggesting that orexin-A reinstated drug seeking through induction of a stress-like 
state (see below). Therefore, the orexin-A and stress systems may closely interact to 
regulate cocaine-seeking behavior [110]. 
These findings highlight the key role of orexin in the mechanisms of reward 
and drug addiction. Indeed, orexin knockout mice develop attenuated morphine 
dependence as compared to wild-type controls, as measured by physical withdrawal 
responses [111]. Interestingly, narcolepsy patients with daytime sleepiness who were 
treated with amphetamine-like stimulants and/or GHB for a long time rarely 




Orexin peptides and emotional states 
Under fearful conditions, animals exhibit increased arousal and vigilance 
levels, accompanied by increased sympathetic outflow and HPA axis activity. Orexin 
neurons are likely to be involved in the coordinated regulation of these responses in 
stressful environments (Fig. 3). The PFA, in which orexin neurons reside, is known to 
be the center of defense responses, or the “fight or flight” response, which is 
characterized by a coordinated rise in arterial blood pressure, heart rate, and 
respiratory frequency [113, 114]. These defense responses are induced by activation 
of the BST and amygdala, or other regions involved in emotional responses. Recent 
tracing studies identified innervation to orexin neurons from several regions of the 
limbic system (a set of brain structures critical for processing of emotional 
information), including the amygdala, infralimbic cortex, NAc shell, lateral septum, 
and BST [49, 50]. The importance of projections from the limbic system to orexin 
neurons is readily apparent in defense responses. As compared with wild-type mice, 
orexin knockout mice and orexin neuron-ablated mice exhibited diminished 
cardiovascular and locomotor responses to the emotional stress evoked by resident-
intruder tests and air-jet stress, respectively [90, 91]. 
Orexin also affects the HPA axis. Orexin neurons innervate the paraventricular 
hypothalamic nucleus (PVN) [5, 6], which abundantly expresses OX2R [9, 10] and 
regulates hypothalamic outflow to the pituitary and the autonomic system. ICV 
administration of orexin-A increases the blood concentrations of corticotropin 
(ACTH) and corticosterone [34, 115] and strongly activates CRF-expressing neurons 
in the PVN and the central nucleus of the amygdala [116]. Consistent with their 
expected roles in the stress response, orexin neurons were activated by cold exposure 
or immobilization stress [116]. On the other hand, orexin neurons receive projections 
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from CRF neurons, and some of these cells (8 out of 32 examined) are directly 
activated by CRF through the CRF-R1 receptor [117]. Indeed, activation of orexin 
neurons by foot shock stress is severely impaired in CRF-R1-deficient mice [117]. 
Thus, a reciprocal link between the CRF system and orexin neurons may play an 
important role in coordinated regulation of arousal and the HPA axis. 
As for positive emotional stimuli, neural input from the limbic system to 
orexin neurons may be implicated in the pathophysiology of cataplexy. In narcoleptic 
dogs, cataplexy is triggered by recognition of highly palatable food and excited play, 
but not by noxious stimuli or unfamiliar environments [118]. In mice, cataplexy is 
most frequently observed when animals are grooming, exploring, burrowing, and 
investigating the environment [12, 21]. In humans, cataplexy is most frequently 
elicited by laughter or pleasure, but not sadness or pain [118-120]. These facts suggest 
that activation of orexin neurons by positive emotion is required to prevent 
undesirable muscle atonia. Orexin neurons project to the mesencephalic locomotor 
region (MLR) and the PPT/LDT in the midbrain; cholinergic neurons in the PPT/LDT 
are implicated in REM-related atonia [48]. Local injection of orexin-A into the MLR 
enhances its activity, while injection into the PPT inhibits REM-related atonia in cats. 
Thus, limbic signals to the midbrain may induce locomotor activity and muscle tone 
when the orexinergic system functions normally, but elicit atonia (cataplexy) when 
orexinergic function is disturbed [48]. Indeed, orexin neurons are maximally active 
during exploratory behavior, and are less but still highly active during grooming and 
eating, whereas they are much less active during food aversion, which is manifested 
as repeated approaches to and withdrawal from a novel food and would not be 
expected to reflect positive emotion, despite the presence of comparable motor 
activity among these behaviors [63]. 
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Projections to orexin neurons from the limbic system may also be important 
for maintaining activity of orexin neurons during the active period by conveying 
various emotional stimuli to orexin neurons. In addition, the limbic input to orexin 
neurons may be involved in the regulation of feeding behavior as well, since some of 
the affective content of the perception of food processed in the amygdala and limbic 
system may be passed on to orexin neurons [121]. 
 
Orexin peptides and nociception 
 Orexin-immunoreactive fibers innervate the spinal cord, especially dorsal root 
ganglion (DRG) neurons and lamina I and X surrounding the central canal [7]. OX1R 
is localized on C-fibers in the spinal cord [122]. These data suggest that the spinal 
orexin system is involved in transmission of nociceptive information. Several studies 
have shown that orexin-A produces analgesic effects in rats [123, 124]. A recent study 
reported a critical role of orexin neurons in stress-induced analgesia (SIA) [125]. 
Orexin neuron-ablated mice did not exhibit SIA, although analgesia was induced by 
ICV administration of orexin-A. Nociceptin/orphanin FQ (N/OFQ) peptide blocked 
SIA in wild-type mice, while coadministration of orexin-A overcame N/OFQ 
inhibition of SIA. N/OFQ-containing fibers form synaptic contacts on orexin neurons 
and inhibit them. These results suggest that the CRF and the N/OFQ systems 
modulate orexin neurons in a coordinated manner to regulate SIA, a key component 
of the defensive behavioral “fight or flight” response [125]. 
 
Orexin peptides and circadian rhythm 
 Direct input to orexin neurons from the suprachiasmatic nucleus (SCN), in 
which the central circadian clock is located, seems to be sparse. Orexin neurons, 
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however, receive abundant innervations from the BST, the supraventricular zone, and 
the DMH [49, 50], all of which receive input from the SCN [126]. This indicates that 
orexin neurons may receive signals indirectly from the SCN via these regions to 
regulate the circadian rhythm of the sleep/wake cycle.  
 For animals to survive effectively, the timing of feeding-related behavior 
should be appropriately coordinated both with the environmental conditions, such as 
food availability and risk of predation, and with the internal physiological state, such 
as gastrointestinal function and energy balance. The central circadian clock in the 
SCN is regulated according to environmental light/dark cues conveyed from the eye 
(light-entrainable oscillator, LEO) [127]. Independently of LEO, daily restricted 
feeding (in which food availability is restricted to a single period scheduled at a fixed 
time of the day) produces an anticipatory increase in locomotor activity (FAA), as 
well as in many physiological events, in the hours preceding food availability [128]. 
These changes in biological rhythms have been postulated to be brought about by the 
FEO, independent of the central circadian clock in the SCN. Orexin neuron-ablated 
mice showed a severe deficit in the normal food anticipatory increases in wakefulness 
and locomotor activity under restricted feeding [97, 98]. Moreover, activity of orexin 
neurons markedly increased during the food-anticipatory period under restricted 
feeding in wild-type mice. Since entrainment to feeding per se seemed to be normal in 
both genotypes, orexin neurons are suggested to function in an efferent pathway of a 




Integration of external and internal environmental information by orexin 
neurons 
 In summary, not only do orexin neurons contribute to sleep/wake regulation by 
stabilizing the activity of wake-promoting neural circuits, they are involved in sensing 
the body’s external and internal environments, and regulate states of sleep and 
wakefulness accordingly, which is beneficial for survival (Fig. 3). They further 
coordinate autonomic tone and hormonal balance with arousal to maintain 
homeostasis or homeodynamics. In addition, orexin neurons may have a direct impact 
on feeding and the reward system in a manner independent of sleep/wake regulation. 
Thus, the reciprocal interactions between orexin neurons and multiple neuronal 
systems raise the possibility that orexin neurons function as an interface between 
multiple regulatory systems including feeding, reward, emotional, circadian, 
autonomic, and endocrine systems. 
 
As yet unrecognized physiological roles of orexin peptides 
Using transgenic mice in which a genetically encoded calcium indicator 
(Yellow Cameleon, Yc2.1) is expressed specifically in orexin neurons, we have 
screened for factors that affect the activity of these neurons [101]. This screen not 
only confirmed the effects of several factors, including GABA, glucose, serotonin, 
noradrenaline, and leptin, that had been shown to have an influence on orexin neurons 
by slice electrophysiological studies, but also identified a sulphated octapeptide form 
of cholecystokinin (CCK-8S), neurotensin, oxytocin, and AVP as novel activators of 
orexin neurons, leading to further elucidation of the physiological interaction between 
AVP and orexin neurons in water deprivation-derived hyperactivity as described 
earlier [100]. Studies using electrophysiological, pharmacological, behavioral, and 
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physiological techniques on other activators of orexin neurons in wild-type mice, as 
well as mutant mice in which receptors for these activators are deleted specifically in 
orexin neurons, would further uncover unexpected roles of orexin neurons in the 
regulation of behavior and physiology. 
 
Conclusion and perspective 
Symptoms of narcolepsy-cataplexy unequivocally reveal that orexins and 
orexin receptors play crucial roles in regulation of sleep/wake states. In addition, the 
existence of reciprocal connections between the orexin system and multiple neuronal 
systems indicates that orexin neurons provide crucial links between multiple brain 
functions, such as energy homeostasis, the reward processing, emotion, and arousal. 
Future studies with full use of mouse molecular genetics, such as selective deletion of 
the gene for a particular receptor or signaling molecule in orexin neurons, might lead 
to further understanding of the integrative physiology orchestrated by the orexin 
system. 
From the clinical perspective, discovery of the linkage between the orexin 
system and human narcolepsy-cataplexy has led to the development of a novel means 
of diagnosis of this disease and to the expectation of the discovery and ultimate 
development of novel drugs for the treatment of narcolepsy-cataplexy. Moreover, 
future studies may enable us to understand why orexin neurons degenerate in 
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NREM = non-REM 
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Fig. (1). Sleep state abnormalities in orexin receptor-knockout mice. 
Typical representative 12 hour dark period (20:00–08:00) hypnograms for wild-type 
(WT), OX1R knockout (OX1R KO), OX2R knockout (OX2R KO) and double-receptor 
knockout mice (OX1R/OX2R DKO), all on a C57B/6J background, are shown. The 
different levels above the baseline indicate states of sleep and wakefulness (REM, 
rapid eye movement (REM) sleep; NREM, non-REM (NREM) sleep; Wake, awake) 
of the mouse at the time. Episodes of direct transition from wakefulness to REM sleep 
are shown by red arrowheads. Note the greater awake/NREM sleep episode 
fragmentation and reduced duration of wakefulness in the hypnograms of OX2R 
knockout and double-receptor knockout mice compared with wild-type and OX1R 
knockout mice. Episodes of direct transition from wakefulness to REM sleep were not 
observed in OX1R knockout mice, and were hardly observed in OX2R knockout mice, 
whereas they were frequently observed in double-receptor knockout mice. 
Hypnograms were obtained by simultaneous electroencephalographic (EEG) and 
electromyographic (EMG) recording for 4 weeks (N = 18–40). 
 
Fig. (2). Schematic drawing showing main projections of orexin neurons. 
This figure summarizes predicted orexinergic projections in the human brain. The 
distributions of orexin fibres and receptors (OX1R, OX2R) are predicted from the 
results of studies on rodent brains, as most histological studies on the orexin system 
have been carried out on rodents. Circles show regions with strong receptor 
expression and dense orexinergic projections. Orexin neurons originating in the lateral 
hypothalamic area (LHA) and posterior hypothalamus (PH) regulate sleep and 
wakefulness and the maintenance of arousal by sending excitatory projections to the 
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entire CNS, excluding the cerebellum, with particularly dense projections to 
monoaminergic and cholinergic nuclei in the brain stem and hypothalamic regions [4-
6, 10, 32, 42, 43, 103, 129], including the locus coeruleus (LC, containing 
noradrenaline), tuberomammillary nucleus (TMN, containing histamine), raphe nuclei 
(raphe, containing serotonin) and laterodorsal/pedunculopontine tegmental nuclei 
(LDT/PPT), containing acetylcholine). Orexin neurons also have links with the 
reward system through the ventral tegmental area (VTA, containing dopamine) and 
with the hypothalamic nuclei that stimulate feeding behavior. Anatomical image 
adapted, with permission, from [130]. 
 
Fig. (3). Interactions of orexin neurons with other brain regions implicated in 
sleep and wakefulness. 
Orexin neurons in the lateral hypothalamic area (LHA) and posterior hypothalamus 
(PH) are anatomically well placed to provide a link between the limbic system, 
systems involved in energy homeostasis, and monoaminergic and cholinergic neurons 
in the brain stem. Solid arrows show excitatory projections, and broken lines 
inhibitory ones. Wake-active regions, sleep-active regions and REM-active regions 
are shown by red, blue and green boxes, respectively. Orexin neurons promote 
wakefulness through the monoaminergic nuclei that are wake-active. Stimulation of 
dopaminergic centers by orexins can modulate reward systems (purple). Peripheral 
metabolic signals such as leptin, ghrelin and glucose influence orexin neuronal 
activity to coordinate arousal and energy homeostasis. The nucleus suprachiasmaticus 
(SCN), the central body clock, sends signals to orexin neurons via the dorsomedial 
hypothalamus (DMH). Input from the limbic system (amygdala and bed nucleus of 
the stria terminalis (BST)) might regulate the activity of orexin neurons upon 
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presentation of emotional stimuli that evoke emotional arousal or fear-related 
responses. VLPO, ventrolateral preoptic area; DR, dorsal raphe; GABA, γ-
aminobutyric acid; LC, locus coeruleus; LDT, laterodorsal tegmental nucleus; PPT, 
pedunculopontine tegmental nucleus; SNr, substantia nigra pars reticulata; TMN, 
tuberomammillary nucleus. 
 
Fig. (4). Mechanisms by which the orexin system stabilizes sleep and 
wakefulness. 
The figure represent the functional interactions between orexin neurons, 
monoaminergic wake-active centers and the ventrolateral preoptic area (VLPO) sleep-
active center during various states of sleep and wakefulness. Red arrows show 
excitatory input, and blue arrows inhibitory input. The thickness of arrows represents 
the relative strength of excitatory and inhibitory input, respectively. Circle sizes 
represent relative activities of each region. (a) Awake state. Orexin neurons send 
excitatory influences to monoaminergic neurons, which send inhibitory feedback 
projections to orexin neurons. This system might maintain the activity of 
monoaminergic neurons. A slight decrease in input to the monoaminergic neurons 
results in decreased inhibitory influence on orexin neurons. Orexin neurons, therefore, 
are disinhibited and have an increased excitatory influence on monoaminergic cells to 
maintain their activity. These monoaminergic cells send excitatory projections to the 
thalamus and cerebral cortex, and send inhibitory projections to the VLPO sleep 
center. These mechanisms maintain wakefulness states. (b) Sleep state. VLPO sleep-
active neurons are activated and send inhibitory projections to monoaminergic 
neurons and orexin neurons to maintain sleep. (c) Narcolepsy. If orexin neurons are 
removed, monoaminergic neurons and VLPO neurons set up a mutually inhibitory 
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circuit, which can cause unwanted and abrupt transitions between the wake/sleep 
states. Activity in one of the competing sides shuts down inhibitory input from the 
other side, and therefore disinhibits its own action. So, when either side begins to 
overcome the other, there is an abrupt switch to the alternative state. 
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